Sustained Tumor Control With MAPK Inhibition in BRAF V600-Mutant Adult Glial and Glioneuronal Tumors.

Giulia BerzeroLuisa BelluCapucine BaldiniFrançois DucrayDavid GuyonMarica EoliAntonio SilvaniCaroline DehaisAhmed IdbaihNadia YounanLudovic Nguyen-ThemStephan GaillardFrancesco PasqualettiCoralie Lepage-SeydouxSakina SekkatePatricia TrescaAurélie KasJulie GratieuxSamy AmmariEdouard SaragoussiJulien SavatovskyJean-Yves DelattreKhê Hoang-XuanDavid MeyronetChiara VillaFranck BielleMarc SansonMehdi TouatAnna Luisa Di Stefano

Published in: Neurology (2021)

This study provides Class III evidence that, for adult patients with BRAF V600-mutant GGNT, RAFi/MEKi can reduce tumor burden and provide clinical benefit.

Keyphrases

wild type
signaling pathway
metastatic colorectal cancer
neuropathic pain
risk factors
cell proliferation
spinal cord injury
pi k akt